STX-721

1 Cited Publications
Revisión del cliente

Based on 1 publication(s) in Google Scholar

STX-721 is an orally active, irreversible, covalent EGFR exon 20 insertion (ex20ins) inhibitor that selectively targets ex20ins-mutant dynamic protein states. STX-721 potently inhibits the kinase activity of EGFR ex20ins mutants (NPG, ASV, SVD). STX-721 inhibits phosphorylation of EGFR (pEGFR Y1068) and downstream ERK (pERK Thr202/Tyr204), and suppresses proliferation of ex20ins-mutant Ba/F3 cells and human NSCLC cell lines (NCI-H2073 ASV KI, CUTO-14 ASV). STX-721 induces tumor regression in EGFR ex20ins-mutant PDX/CDX models. STX-721 can be used for the study of non-small cell lung cancer (NSCLC) harboring EGFR or HER2 ex20ins mutations.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 98.25%
  • No. CAS: 2765525-82-2
  • Fòrmula: C32H35ClN6O3
  • Peso molecular:587.11
  • Almacenamiento:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
You May Still Need

Publications Citing Use of MedChemExpress (MCE) STX-721

More

Ver todos los productos específicos de isoformas EGFR

More

Ver todos los productos específicos de isoformas ERK

More
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00